Publication Name	World Journal of Gastroenterology
Manuscript ID	18382
Country	Türkiye

Received	2015-04-21 09:47
Peer-Review Started	2015-04-21 11:54
To Make the First Decision	2015-06-19 17:56
Return for Revision	2015-06-20 18:17
Revised	2015-07-02 07:10
Second Decision	2015-10-10 18:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-10-13 17:44
Articles in Press	2015-10-13 17:44
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-11-05 06:07
Typeset the Manuscript	2016-01-07 16:10
Publish the Manuscript Online	2016-01-20 16:55

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations
Manuscript Source	Unsolicited Manuscript
All Author List	Aylin Calica Utku and Oguz Karabay
Funding Agency and Grant Number
Corresponding Author	Dr. Aylin Calica Utku, Department of Infectious Diseases and Clinical Microbiology, Sakarya University Training and Research Hospital, Street of Adnan Menderes, 54200 Sakarya, Turkey. aylindoctor@hotmail.com
Key Words	Hepatitis B; Lamivudine; Tyrosine-methionine-aspartate-aspartate mutation; Drug resistance; Treatment
Core Tip	Lamivudine is a nucleoside analogue that has been used in treatment of chronic hepatitis B. The only drawback of lamivudin is drug resistance during the treatment. Entecavir and tenofovir are potent hepatitis B virus inhibitors with a high barrier to resistance . They can used as first-line monotherapies. The main problem of lamivudine treatment is development of mutation in the tyrosine-methionine-aspartate-aspartate (YMDD) motif. Treatment with lamivudine may cause exacerbation of hepatitis in patients with YMDD mutation. These patients should use YMDD mutant form-effective drugs.
Publish Date	2016-01-20 16:55
Citation	Calica Utku A, Karabay O. Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations. World J Gastroenterol 2016; 22(4): 1727-1728
URL	http://www.wjgnet.com/1007-9327/full/v22/i4/1727.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i4.1727

Full Article (PDF)	WJG-22-1727.pdf
Full Article (Word)	WJG-22-1727.doc
Manuscript File	18382-Review.doc
Answering Reviewers	18382-Answering reviewers.pdf
Audio Core Tip	18382-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18382-Conflict-of-interest statement.pdf
Copyright License Agreement	18382-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18382-Language certificatent.pdf
Peer-review Report	18382-Peer-review(s).pdf
Scientific Misconduct Check	18382-Scientific misconduct check.pdf
Scientific Editor Work List	18382-Scientific editor work list.pdf